Truist upgraded pain therapy developer Pacira BioSciences (NASDAQ:PCRX) to Hold from Sell on Thursday, noting that the ...

This was the stock's second consecutive day of gains.

Truist Securities upgraded Pacira Pharmaceuticals (NASDAQ:PCRX) stock rating from Hold to Buy, significantly raising the price target to $25.00 from the previous $8.00. The stock, currently trading at ...

Truist raised the firm’s price target on Tesla (TSLA) to $373 from $351 but keeps a Hold rating on the shares. The company’s Q4 results saw ...

Truist Financial analyst Michael Roxland reiterated a Buy rating on Silgan Holdings (SLGN – Research Report) today and set a price target of ...

Net interest margin, which measures lending profitability, expanded to 3.07%, compared with 2.95% a year earlier. Truist's ...

Leaders at the bank, which has been operating in DFW for more than a decade, want to capitalize on positive trends.

Truist Financial's Q4 beat EPS and revenue estimates, but noninterest expenses rose and specific lending segments faced ...

Influence Media Partners (“Influence Media” or “Influence”) — a leading music and entertainment company focused on partnering with and investing in to ...

Money from the program will be used by nonprofit groups to help rebuild small businesses, housing and infrastructure in 39 ...

Truist Financial Corp. continued to settle into its trimmer fee-income strategy during the fourth quarter by slightly ...